Doxorubicin-Teva

Country of origin: Israel, Teva Pharmaceutical Companies/Pharmachemi Netherlands

Pharm-Group: Antitumor antibiotics

Manufacturers: Teva Pharmaceutical Enterprises Ltd. (Israel), Teva Pharmaceutical Enterprises/Pharmachemi (Netherlands)

International name: Doxorubicin

Synonyms: Adriamycin, Adriblastin, Adriblastin instant, Blastocin, Doxolem, Doxorubicin, Doxorubicin-Lance, Doxorubicin-Ferein, Doxorubicin-Ebeve, Doxorubicin hydrochloride, Kelix, Rastocin

Dosage forms: lyophilized powder for the preparation of injection solution 10 mg, lyophilized powder for the preparation of injection solution 50 mg

Composition: Active ingredient - doxorubicin.

Indications for use: Acute lymphoblastic and myeloblastic leukemia; malignant lymphoma of Hodgkin and non-Hodgkin type; cancer of the breast, lung (especially small cell), bladder, thyroid, ovarian; osteogenic sarcoma; soft tissue sarcoma; Ewing's sarcoma; neuroblastoma; Wilms tumor.

Contraindications: Hypersensitivity to hydroxybenzoates, severe suppression of bone marrow function due to taking other chemotherapy drugs or radiation therapy, previous treatment with anthracyclines in maximum total doses, leukopenia, thrombocytopenia, anemia, severe liver and kidney dysfunction, acute hepatitis, bilirubinemia, severe heart disease (myocarditis, severe rhythm disturbances, acute phase of myocardial infarction), gastric and duodenal ulcers, bleeding, tuberculosis, cystitis (intravesical administration), pregnancy, breastfeeding. Restrictions on use: Age under 2 years and after 70 years (possible increase in the frequency of cardiotoxic effects), organic heart damage (risk of developing cardiotoxic effects at low doses).

Side effect:

1. From the cardiovascular system and blood (hematopoiesis, hemostasis): congestive heart failure, acute atrial and ventricular arrhythmia, toxic myocarditis, thrombocytopenia, leukopenia, phlebosclerosis, flushing of the face and hyperemia along the vein.

2. From the gastrointestinal tract: nausea, vomiting, stomatitis or esophagitis, ulceration in the gastrointestinal tract; rarely - anorexia, diarrhea.

3. From the genitourinary system: hyperuricemia, nephropathy, reddish color of urine. With intravesical administration - burning in the bladder and urethra, urination disorder, hematuria.

4. From the skin: alopecia, darkening of the soles, palms and nails, relapse of radiation erythema.

5. Allergic reactions: skin rash, itching, fever, chills, anaphylaxis.

6. Other: extravasation, cellulite, necrosis, rarely - conjunctivitis, lacrimation.

Interaction:

1. Pharmaceutically incompatible with some drugs.

2. Strengthens the toxic effect of other antitumor drugs and radiation therapy.

3. Weakens the effect of vaccines.

Overdose: Increased toxic effects. Treatment: antibiotic therapy, granulocyte transfusion, symptomatic treatment of inflammation of the mucous membranes.

Special instructions:

1. Monitoring of blood counts, cardiac activity and liver function is required.

2. Prescribe with caution in patients with reduced bone marrow reserve.

3. Dose adjustment for renal failure.

4. Compliance with the rules of preparation and administration of the drug.

Literature: Encyclopedia of Medicines 2004.